1. Scrip

AstraZeneca & Sputnik V COVID-19 Vaccine Combo To Enter Trial

Russians Claim The Lead In Heterologous Coronavirus Vaccination

 
• By Ian Schofield

There is growing in interest in boosting the first dose of a COVID-19 vaccine by administering a different vaccine as the second dose.

Coronavirus. COVID-19, coronavirus in UK
New approaches to coronavirus vaccination are being trialed • Source: Shutterstock

Clinical trials of a two-dose regimen using the Oxford/AstraZeneca PLC coronavirus vaccine, AZD1222, and Russia’s Sputnik V are to begin in the week of 8 February, initially in Azerbaijan and the United Arab Emirates, according to the Russian Direct Investment Fund, which is financing the development of Sputnik V.

The open-label, randomized Phase I/II study will investigate the safety and immunogenicity of AZD1222 in combination with the recombinant adenovirus type 26 (Ad26) component of the Sputnik V vaccine

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.